KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.

S Y Ryu, W Deng, K Albuquerque, W-J Koh, J Mayadev, A Heugel, B-J Kim, D-Y Kim, C-H Cho, J-W Kim, J H No, R S Mannel, K Miller, D Fabian, D M Chase, K M Gil, W Small, W Rodgers, C A Leath, B J Monk

Ann Oncol 36(12) 1514-1524

PMID40947016
PMCIDPMC12721713
DOI10.1016/j.annonc.2025.09.003
发表日期2025-09-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: To determine whether adjuvant chemoradiation (CRT) with weekly cisplatin improves recurrence-free survival (RFS) compared with radiation (RT) in pathologically proven intermediate risk early-stage cervical cancer following radical hysterectomy and lymphadenectomy. METHODS: Post-surgical patients with stage I-IIA cervical cancer with pathologically noted intermediate risk factors including combinations of capillary lymphatic space involvement, stromal invasion, and tumor size were randomly assigned in a 1 : 1 ratio to receive either adjuvant CRT or RT (NCT01101451). Patients received conformal RT, or intensity modulated radiation therapy. In the CRT arm, 6 weekly cycles of cisplatin 40 mg/m2 were administered during RT. RFS was the primary endpoint in randomized and eligible patients. Secondary endpoints included overall survival (OS), quality of life (QoL), and adverse events (AEs). RESULTS: Of the 340 randomized patients, 316 were eligible and most had Federation of Gynecology and Obstetrics (2009) stage IB1 and squamous cell carcinoma histology. Out of 316 patients, 292 (92.4%) received 28 fractions of RT with a median dose of 50.4 Gy and a median treatment duration of 39 days. Three-year RFS was 88.5% in the CRT arm and 85.4% in the RT arm. Both RFS [hazard ratio (HR) 0.698, 95% confidence interval (CI) 0.408-1.192, P = 0.09], as well as OS [HR 0.586, 95% CI 0.286-1.199, P = 0.07] favored CRT compared with RT alone. Grade 3 or 4 AEs occurred in 43% and 15% in the CRT and RT arms, respectively (P < 0.01). A transient decline in QoL occurred in the CRT arm compared with RT after starting treatments and recovered to pre-treatment level by 36 weeks. CONCLUSION: Although RFS and OS favored CRT, the addition of cisplatin during RT did not statistically improve RFS or OS in cervical cancer patients with intermediate pathological risk factors following radical hysterectomy and lymphadenectomy. CRT increased grade 3 and 4 AEs with a transient decline in QoL.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2.

a) Recurrence-Free Survival (RFS) by Kaplan-Meier method per randomized therapy (3-year RFS: 88.5% in CRT arm and 85.4% in RT arm respectively, p = 0.09). b) Overall Survival (OS) by Kaplan-Meier method per randomized therapy (3-year OS: 97.2% in CRT arm and 90.3% in RT arm respectively, p = 0.07). c) Forest plot for recurrence-free survival treatment effect by subgroup analyses. Confidence intervals should not be used to reject or not reject the null hypothesis of a treatment effect. RT; radiation treatment only, CRT; concurrent chemo-radiation treatment, CI; confidence interval, RFS; recurrence free survival, OS; overall survival, CLS; capillary lymphatic space involvement, Strata: stratification used at randomization, IMRT; intensity modulated radiation treatment, XRT; external beam radiation treatment, GOG; Gynecologic Oncology Group, KGOG; Korean Gynecologic Oncology Group

A

Recurrence-Free Survival

Figure 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Consort Diagram for patients enrolled on GOG263
非 KM Figure